Delegates discover the benefits of PerioChip® at EuroPerio 8
Delegates at EuroPerio 8 could see first hand that PerioChip® is passionate about supporting, educating and communicating with the dental community to highlight the importance of keeping gums healthy, and treating periodontitis effectively without the risk associated with using antibiotics.
By using PerioChip® you can ensure that harmful bacteria in and around the gingiva are eliminated for up to 10 daysi and, for on-going therapy, PerioChip® suppresses the growth of bacterial flora in the treated site for up to 11 weeks, giving the all-important time needed for gum reattachment and stabilisation of the periodontiumii.
EuroPerio 8 was a fantastic venue for PerioChip® to raise awareness amongst the dental community about gum disease the links to systemic illnesses such as diabetes and cardiovascular disease. The speakers taking to the stage at the show to share their knowledge included: Professor Eli Machtei, Professor Arie J Van Winkelhoff and Dr Rajan Nansi, and attendees were wowed by their passion and expertise for the subject.
If you missed out on attending EuroPerio 8 and want to learn more about PerioChip® email This email address is being protected from spambots. You need JavaScript enabled to view it. or call 0800 013 2333 today!
i Jeffcoat M K et al. Adjunctive use of a subgingival controlled-release chlorhexidine chip. J Periodontal 1998; 69 (9): 989 – 997. http://www.ncbi.nlm.nih.gov/pubmed/9776027 [Accessed 26th May 2015]
ii Summary of Characteristics PerioChip® http://www.old.health.gov.il/units/pharmacy/trufot/alonim/PerioChip_dr_1337488974840.pdf [Accessed 26 May 2015]
About the author
Related Posts
Comments
By accepting you will be accessing a service provided by a third-party external to https://www.gdpuk.com/
GDPUK Ltd announces sale of intellectual property to leading publisher Cogora Group
GDPUK Ltd today announces the sale of its intellectual property assets to Cogora Group, one of the UK's leading publishers of healthcare brands, events and educational platforms.
The decision to sell GDPUK’s intellectual property forms part of a considered transition to ensure the long‑term stewardship and development of the brand and associated assets. Cogora brings a wealth of experience and expertise to support the continued evolution of the dentistry brand within its wide portfolio of market-leading healthcare publications. Its award-winning titles include Pulse, a long‑standing and widely recognised source of political news and clinical education for GPs, Nursing in Practice, Management in Practice, The Pharmacist, Pulse PCN and Healthcare Leader, as well as two secondary care publications – Hospital Healthcare Europe and Hospital Pharmacy Europe. The purchase will cement Cogora as the biggest publisher of primary care titles in the UK and allow it to bring its expertise in providing news, analysis, opinion and groundbreaking stories to GDPUK, as well as continue giving dentists and dental staff a voice through its website.
“After careful consideration, we believe that Cogora is well positioned to take GDPUK’s intellectual property forward,” said Tony Jacobs, founder, editor and publisher of GDPUK.com . “This transaction provides continuity for the professional community associated with GDPUK and creates opportunities for future growth under experienced ownership.”
Tony will continue involvement in GDPUK on a consulting basis.
GDPUK Ltd has worked to ensure an orderly transfer of the intellectual property and wishes Cogora every success in its future development.